Redhill Biopharma Stock Probability of Future Stock Price Finishing Under 6.99
| RDHL Stock | USD 6.74 0.34 5.31% |
Redhill |
Redhill Biopharma Target Price Odds to finish below 6.99
The tendency of Redhill Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 6.99 after 90 days |
| 6.74 | 90 days | 6.99 | about 7.6 |
Based on a normal probability distribution, the odds of Redhill Biopharma to stay under $ 6.99 after 90 days from now is about 7.6 (This Redhill Biopharma probability density function shows the probability of Redhill Stock to fall within a particular range of prices over 90 days) . Probability of Redhill Biopharma price to stay between its current price of $ 6.74 and $ 6.99 at the end of the 90-day period is roughly 2.68 .
Given the investment horizon of 90 days Redhill Biopharma has a beta of 0.41 indicating as returns on the market go up, Redhill Biopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Redhill Biopharma will be expected to be much smaller as well. Additionally Redhill Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Redhill Biopharma Price Density |
| Price |
Predictive Modules for Redhill Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Redhill Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Redhill Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Redhill Biopharma is not an exception. The market had few large corrections towards the Redhill Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Redhill Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Redhill Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | 0.41 | |
σ | Overall volatility | 1.14 | |
Ir | Information ratio | -0.14 |
Redhill Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Redhill Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Redhill Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Redhill Biopharma generated a negative expected return over the last 90 days | |
| Redhill Biopharma has high historical volatility and very poor performance | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Redhill Biopharma currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Redhill Biopharma's use of debt, we should always consider it together with its cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Latest headline from finance.yahoo.com: Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV |
Redhill Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Redhill Stock often depends not only on the future outlook of the current and potential Redhill Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Redhill Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.5 M | |
| Cash And Short Term Investments | 6.4 M |
Redhill Biopharma Technical Analysis
Redhill Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Redhill Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Redhill Biopharma. In general, you should focus on analyzing Redhill Stock price patterns and their correlations with different microeconomic environments and drivers.
Redhill Biopharma Predictive Forecast Models
Redhill Biopharma's time-series forecasting models is one of many Redhill Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Redhill Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Redhill Biopharma
Checking the ongoing alerts about Redhill Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Redhill Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Redhill Biopharma generated a negative expected return over the last 90 days | |
| Redhill Biopharma has high historical volatility and very poor performance | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Redhill Biopharma currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Redhill Biopharma's use of debt, we should always consider it together with its cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Latest headline from finance.yahoo.com: Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV |
Check out Redhill Biopharma Backtesting, Redhill Biopharma Valuation, Redhill Biopharma Correlation, Redhill Biopharma Hype Analysis, Redhill Biopharma Volatility, Redhill Biopharma History as well as Redhill Biopharma Performance. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.